We discovered that blocking the interaction of CMTR1 with ELAVL1 via SNORA37 knockdown was able to repress tumorigenesis and aggressiveness, indicating the value of SNORA37/CMTR1/ELAVL1 axis as a therapeutic target for cancers. The gene discussed is ELAVL1; the disease is cancer.